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Matrix metalloproteinase 2 (MMP-2) and MMP-9 are increased in human choroidal 
neovascularization (CNV) occurring during the exudative most aggressive form of age-related 
macular degeneration (AMD), but their precise role and potential interactions remain unclear. To 
address the question of MMP-2 and MMP-9 functions, mice deficient in the expression of MMP-
2 (MMP-2 KO), MMP-9 (MMP-9 KO), and both MMP-2 and MMP-9 (MMP-2,9 KO) with their 
corresponding wild-type mice (WT) underwent CNV induction by laser-induced rupture of the 
Bruch's membrane. Both the incidence and the severity of CNV were strongly attenuated in 
double deficient compared with single gene deficient mice or corresponding WT controls. The 
reduced neovascularization was accompanied by fibrinogen/fibrin accumulation. Furthermore, 
overexpression of the endogenous MMP inhibitors TIMP-1 or TIMP-2 (delivered by adenoviral 
vectors) in WT mice or daily injection of a synthetic and gelatinase selective MMP inhibitor (Ro 
26-2853) significantly decreased the pathological reaction. These findings suggest that MMP-2 
and MMP-9 may cooperate in the development of AMD and that their selective inhibition 
represents an alternative strategy for the treatment of choroidal neovascularization. 
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he abrupt and often definitive loss of visual function resulting from choroidal 
neovascularization, which occurs in the exudative form of age-related macular 
degeneration (AMD), is a worldwide health problem with the aging population (1). It is 
estimated that by their 90s, one in four people will have lost vision from AMD (2). 
T 
 Although the primary stimulus for the development of retinal neovascularization is hypoxia, the 
exact molecular signals involved in the appearance and growth of pathological choroidal 
neovascularization are not well defined (3). The net balance between positive and negative 
regulatory molecules controls angiogenesis (4). Vascular endothelial factor (VEGF) and 
pigment-epithelium derived factor (PEDF) are expressed in AMD and play an important role in 
choroidal neovascular membrane formation (57). Their contribution is further supported by the 
previous demonstration that either inhibition of the VEGF system or overexpression of PEDF 
efficiently inhibited choroidal neovascularization (8, 9). However, angiogenesis is also 
associated with an important extracellular remodeling involving different proteolytic systems, 
among which the matrix metalloproteinases (MMPs) play an essential role (10, 11). 
The MMPs are a family of zinc- and calcium-dependent proteases that are capable of degrading 
the extracellular matrix (ECM) and basement membrane (10, 11). They are believed to play 
pivotal roles in embryonic development and growth (12, 13), as well as in tissue remodeling and 
repair (14, 15). Excessive or inappropriate expression of MMPs may therefore contribute to the 
pathogenesis of many tissue-destructive processes, including tumor progression (10, 11) and 
aneurysm formation (16). MMP effects are not restricted to ECM degradation (17). For example, 
peptide growth factors that are sequestered by ECM proteins become available once degraded by 
MMP-9 (18). MMPs can increase the bioavailability of VEGF (19) but also generate 
angiogenesis inhibitors such as angiostatin by cleavage of plasminogen (20). 
A possible involvement of MMPs has been suggested in the progression of both retinal and 
choroidal neovascularization, and mutations in the TIMP-3 gene (tissue inhibitor of 
metalloproteinases-3) are the cause of a rare familial form of macular dystrophy associated with 
subretinal neovascularization (2123). Using an experimental murine model of laser-induced 
choroidal neovascularization, we have recently demonstrated that MMP-9 secretion from 
inflammatory cells contributes to the development of pathological choroidal angiogenesis (24). 
The magnitude of angiogenesis inhibition produced by MMP-9 deficiency was, however, minor 
compared with that observed previously in the same model in mice deficient for plasminogen 
activator inhibitor type I (PAI-1; ref 25). This suggests that MMP-9 is not the only pathway for 
rendering angiogenic factors bioavailable, which clearly occurs in other experimental settings 
(19). Indeed, both MMP-9 and MMP-2 are expressed in human choroidal neovascular 
membranes removed during surgery for late stage AMD (26), while MMP-2 is the predominant 
MMP expressed during rat choroidal neovascularization formation (27). Furthermore, other 
investigators have pointed out that, depending on the specific context, these gelatinases could 
either work in concert or antagonistically (28, 29). 
To address the question of MMP-2 and MMP-9 functions, we investigated the expression and 
activity of members of the MMP system in different stages of laser-induced murine choroidal 
neovascularization, comparing choroidal neovascularization formation in single (MMP-9 KO, 
MMP-2 KO) or double (MMP-2,9 KO) deficient mice compared with wild-type (WT) controls. 
 METHODS 
Genetically modified mice 
MMP-2−/− mice (30) and MMP-9−/− mice (13) were crossed with each other to obtain MMP-
2+/−MMP-9+/− mice. These mice were intercrossed to obtain MMP-2−/−MMP-9−/− (double 
knockout, also designed as MMP-2,9 KO) and control wild-type (WT) MMP-2+/+MMP-9+/+ 
mice. All mice were genotyped using PCR. Animal experiments were performed in compliance 
with the Association for Research in Vision and Ophthalmology (ARVO) statement for the Use 
of Animals in Ophthalmic and Vision Research. The animals were maintained with a 12:12-h 
light/dark cycle and had free access to food and water. 
Experimental choroidal neovascularization 
Choroidal neovascularization was induced in mice by four burns (usually at the 6, 9, 12, and 3 
o'clock positions around the optic disc) using a green argon laser (532 nm; 50 µm diameter spot 
size; 0.05 sec duration; 400 mW) as previously described (24, 25). Mice with haemorrhage or not 
developing an evident bubble at the site of every laser impact (the sign of ruptured Bruch's 
membrane) were excluded from further analysis. Included animals (5 or more in each condition) 
were killed 14 days after laser (except for kinetic mRNA profiles). Before death, fluorescein 
angiograms (intraperitoneal injection of 0.3 ml of 1% fluorescein sodium, Ciba) were performed 
to confirm that laser burns were developing late phase increasing hyperfluorescent spots 
(corresponding to the leakage of fluorescein from newly formed permeable capillaries). The eyes 
were then enucleated and either fixed in buffered 3.5% formalin solution for routine histology or 
embedded in Tissue TeK (Miles Laboratories, Naperville, IL) and frozen in liquid nitrogen for 
cryostat sectioning. Choroidal neovascularization was quantified as previously described (24, 
25). Briefly, frozen serial sections were cut throughout the entire extent of each burn, and the 
thickest region (minimum of 5/lesion) was selected for the quantification. With the use of a 
computer-assisted image analysis system (Olympus Micro Image version 3.0 for Windows 
95/NT, Olympus Optical CO. Europe GmBH), neovascularization was estimated by the ratio 
(B/C) of the thickness from the bottom of the pigmented choroidal layer to the top of the 
neovascular membrane (B) to the thickness of the intact-pigmented choroid adjacent to the lesion 
(C). A mean B/C ratio value was attributed to each laser impact. 
Gelatin zymography 
Choroidal neovascularization was induced in mice by multiple burns (n=30) as described above. 
Animals were killed at different endpoints, and the eyes were enucleated. The posterior segments 
were cut out and immediately snap frozen in liquid nitrogen. Frozen tissues were then pulverized 
in liquid nitrogen, homogenized in buffer (0.1 M Tris-HCl, pH 8.1, 0.4% Triton X-100), and 
centrifuged for 20 min at 5000 g. The pellets were discarded. Aliquots of supernatants were 
mixed with SDS sample buffer and electrophoresed directly as described previously (31). 
In situ zymography was performed by incubating cryosections (7 µm) with 40 µg/ml fluorescein-
conjugated gelatin (Molecular Probes, Eugene, OR) in 50 mM Tris-HCl, pH 7.5, 10 mM CaCl2, 
150 mM NaCl, and 0.05% Brij-35 (Calbiochem) for 12 h at 37°C; sections were washed three 
 times with water and mounted with Vectashield. Gelatinase activity was visualized using 
fluorescent microscopy (32). 
Immunohistochemistry 
Cryostat sections (5 µm thick) were fixed in paraformaldehyde 1% in 0.07 M phosphate buffered 
saline (PBS), pH 7.0, for 5 min or in acetone for 10 min at room temperature and then incubated 
with the primary antibody. Antibodies raised against mouse PECAM (rat monoclonal, 
PharMingen, San Diego, CA; diluted 1/20), mouse MAC-3 (BD Pharming, San Diego, CA), and 
murine fibrinogen/fibrin (goat polyclonal, Nordic Immunological, Tilburg, The Netherlands; 
diluted 1/400) were incubated for 1 h at room temperature. The sections were washed in PBS 
(3x10 min) and appropriate secondary antibody conjugated to peroxidase (HRP) was added: 
rabbit anti-goat IgG (Dako, Glostrup, Denmark, diluted 1/100) and rabbit anti-rat IgG (Sigma-
Aldrich; diluted 1/40) were applied for 30 min. For staining, a drop of AEC+ (Dako, 3-amino-9-
ethylcarbazole) was added and sections were counterstained for 1 min in hematoxylin. 
Specificity of staining was assessed by substitution of nonimmune serum for primary antibody 
(not shown). 
Adenovirus-mediated TIMP-1 and TIMP-2 gene transfer and synthetic MMP inhibitor 
treatment 
Recombinant adenovirus bearing the gene coding for human TIMP-1 or TIMP-2 (AdTIMP-1, 
AdTIMP-2), or an empty control adenovirus (AdRR5) were generated as described previously 
(3334). Twenty-four hours after laser spot production, mice were intravenously injected with 
200 µl of adenovirus (7×108 PFU). On day 14, mice were killed and eyes were excised and 
processed as described above. 
As an alternative way of MMP inhibition, WT mice were intraperitoneally injected with a broad 
spectrum MMP inhibitor (BB-94, British Biotech Pharmaceuticals Ltd., Oxford, UK) or a more 
selective inhibitor (Ro 28-2653, Roche-Diagnostics, Penzberg, Germany) interacting primarily 
with MMP-2, MMP-9, and MT1-MMP (35). The daily injections started either the same day as 
choroidal neovascularization induction (day 0) or at day 5. 
RT-PCR analysis 
To evaluate the kinetic of MMPs mRNA expression by semiquantitative RT-PCR, choroidal 
neovascularization was induced in mice by multiple argon laser burns and animals were killed at 
days 3, 5, 10, 14, 20, and 40. The posterior segments (RPE-choroid complex without neural 
retina) were cut out and immediately frozen in liquid nitrogen. rTth reverse transcriptase RNA 
PCR kit (Applied Biosystems, Foster City, CA) was used, and pairs of primers (Eurogentec, 
Liège, Belgium), oligonucleotides sequences, number of cycles, and expected PCR product size 
are shown in Table 1. The frozen murine tissues were first pulverized using a Dismembrator (B. 
Braun Biotech international, Gmbh Melsungen, Germany), and total RNA was extracted with the 
RNeasy extraction kit (Quiagen, Paris, France) according to the protocol of the manufacturer. 
28S RNA was amplified with an aliquot of 10 ng of total RNA using the GeneAmp 
Thermostable mRNA. Reverse transcription was performed at 70°C for 15 min followed by 2 
min incubation at 95°C for denaturation of RNA-DNA heteroduplexes. Amplification started by 
 15 s at 94°C, 20 s at 60°C, and 10 s at 72°C. RT-PCR products were resolved on 2% agarose gels 
and analyzed using a Fluor-S MultiImager (Bio-Rad) after being stained with ethidium bromide 
(FMC BioProducts). 
Statistical analysis 
Data were analyzed with GraphPad Prism 3.0 (San Diego, CA). The chi-square and Mann-
Whitney tests were used to determine significant (P<0.01) differences between WT and deficient 
mice. 
RESULTS 
Induction of experimental choroidal neovascularization in WT, MMP-2KO, MMP-9KO, 
and MMP-2,9KO mice 
Fluorescein angiography performed before death (Fig. 1F) showed a significant reduction 
(P<0.001) in the number of leaking spots (corresponding to newly formed immature 
microvessels with leakage of fluorescein) in MMP-2,9 double KO mice compared with MMP-2 
or MMP-9 deficient mice. This corresponded to a strong inhibition of neovascular progression 
estimated at day 14 after induction by immunostaining with anti-PECAM antibodies in MMP-2,9 
double KO mice (Fig. 1D), compared with MMP-2 or MMP-9 deficient (Fig. 1B-C) or WT (Fig. 
1A) animals. We then quantified choroidal pathological reaction in sites developing a 
neovascular membrane by measuring, on serial sections, the maximal height of the lesion above 
the choroidal layer observed in neighboring intact zones. This was performed by determining the 
B/C ratio between total thicknesses of lesions (B, from the bottom of the choroid to the top of the 
neovascular area) to the thickness of adjacent normal choroid (C) according to Lambert et al. 
(24, 25). A significant reduction of the B/C ratio was observed in MMP-9 (33%), MMP-2 (44%), 
and MMP-2,9 (56%) deficient mice compared with their corresponding WT (P<0.001, Fig. 1E). 
Presence of MMP-2 and MMP-9 in the posterior segments of WT and MMP deficient mice 
at day 5 and temporal profile during the formation of choroidal neovascularization 
Ocular posterior segment proteins prepared from WT, MMP-9 KO, MMP-2 KO, and MMP-2,9 
KO mice were analyzed by gelatin zymography (Fig. 2A). As expected, no MMP-2 and MMP-9 
activity was detected in MMP-2 KO, MMP-9 KO, and MMP-2,9 KO mice (not shown), 
respectively. WT mice expressed pro-MMP-2 and -MMP-9 as well as processed MMP-2. 
Although the ocular expression of MMP-9 increased in the MMP-2 KO mice, MMP-2 KO mice 
were significantly protected from the development of severe choroidal neovascularization. Both 
pro-MMP-2 and pro-MMP-9 progressively accumulated during the early stages of choroidal 
neovascularization formation, with the appearance of active forms of MMP-2 (Fig. 2B). 
In situ zymography revealed that gelatinase activation in the posterior ocular segments was 
predominantly present in the area developing choroidal neovascularization (Fig. 2C). Although 
gelatinolytic activity was strongly decreased in double MMP-2,9 deficient mice, residual activity 
was still detectable at the top of the choroidal pathological reaction (Fig. 2D). 
 Kinetics of MMP expression 
To evaluate the level of regulation, we first analyzed the temporal profiles of MMP-2 and MMP-
9 expression by semiquantitative RT-PCR. MMP-9 expression was upregulated during early 
phases of choroidal neovascularization formation, whereas MMP-2 (constitutively expressed) 
showed no significant modulation (Fig. 3A-B). We knew from previous work (36) that members 
of the plasminogen system are induced early during the process (important for plasmin-mediated 
activation of pro-MMP-9). The presence of active forms of MMP-2 theoretically could 
correspond either to a decrease of TIMP expression or to an increase in the expression of 
activators (MT1-MMP). RT-PCR analysis demonstrated a constant expression of TIMP-2 but a 
significant upregulation of MT1-MMP mRNA (Fig. 3, B and C). 
Effect of MMP deficiency on fibrinolytic activity 
Plasminogen activators/plasmin play an important role in choroidal neovascularization (24, 36). 
However, MMPs may modulate fibrinolysis through plasminogen-dependent or independent 
mechanisms (3739). We evaluated the immunohistochemical staining of fibrinogen/fibrin, as an 
endpoint of fibrinolytic activity. This demonstrated the presence of similar fibrinogen/fibrin 
deposits in WT and MMP-2 or MMP-9 deficient mice (Fig. 4A-C). However, fibrinogen/fibrin 
accumulated in double MMP-2,9 deficient animals, suggesting that the absence of both 
gelatinases impaired fibrinolytic activity in the choroidal neovascular membrane (Fig. 4D). 
MMP inhibitors decrease the development of choroidal neovascularization 
In a second approach to show that MMPs contribute to the development of choroidal 
neovascularization, we induced endogenous overexpression of TIMP-1 or TIMP-2 with 
adenoviral-mediated delivery in WT mice. RT-PCR analysis of murine posterior segments 
revealed that systemic intravenous injections also led to increased local expressions of TIMP-1 
and TIMP-2 (Fig. 5A-B). Evaluation by in situ zymography demonstrated a complete inhibition 
of gelatinolytic activity after AdTIMP-1 injections, whereas residual activity was still present in 
case of AdTIMP-2 (Fig. 5C-D). The evaluation of choroidal neovascularization formation by 
B/C ratio calculation was compared on serial frozen sections in WT mice 14 days after injection 
with either AdTIMP-1 or AdTIMP-2. Both TIMP-1 and TIMP-2 overexpression significantly 
reduced angiogenesis (P<0.001) compared with WT controls injected with AdRR5 (Fig. 5 E). 
We then evaluated the consequences of broad spectrum (BB-94) or more selective MMP 
inhibitor (Ro 28-2653, a more selective synthetic gelatinase inhibitor acting preferentially on 
MMP-2, MMP-9, and MT1-MMP, ref. 35) inhibition on choroidal neovascularization 
development by treating WT mice with daily systemic injections. Both inhibitors significantly 
reduced the choroidal neovascularization formation. (Fig. 5F). However, Ro 28-2653 was more 
efficient (P<0.001) than BB-94. Interestingly, selective MMP inhibition treatment started 5 days 
after laser induction also significantly inhibited the development of choroidal angiogenesis (40% 
inhibition) indicating thereby a potential for drug-induced regression (Fig. 5F). 
DISCUSSION 
This study shows that both MMP-2 and MMP-9 cooperate in the course of experimental 
choroidal neovascularization. Indeed, choroidal pathological angiogenesis was nearly fully 
 prevented in MMP-2/MMP-9 double deficient mice, whereas it was only partly impaired in the 
single MMP deficient mice (Fig. 1D-F). These results were supported by the strong inhibition of 
choroidal angiogenesis in mice treated with a selective gelatinase/MT1-MMP synthetic inhibitor 
(Fig. 5F). 
Previous studies suggested a role for different MMPs in the exudative form of AMD (2224, 26, 
4041). With the use of MMP deficient mice (MMP-2 KO, MMP-9 KO, and MMP-2,9 KO) and 
different methods of MMP inhibition (AdTIMP-1, AdTIMP-2, BB-94, and Ro 28-2653), our 
observations provide a more complete understanding of the role of the MMP system in choroidal 
neovascularization. MMP-9 mRNA was upregulated, whereas MMP-2 mRNA showed little 
variation during choroidal neovascularization formation. However, MT1-MMP, which is a major 
MMP-2 activator, was strongly induced (10, 11, 42). It is of interest to note that in our model, 
MMP-2 deficiency was accompanied by increased MMP-9 activity detected by gelatin 
zymography, while the opposite was not observed. However, this increase in MMP-9 did not 
prevent the inhibitory consequences of MMP-2 deficiency on choroidal neovascularization 
development (Fig. 1). 
Fibrin and other adhesive proteins such as vitronectin, laminin, and fibronectin form a 
provisional matrix, which supports angiogenesis (43). We have recently demonstrated the 
importance of finely tuned fibrinolysis for the development of subretinal pathological 
angiogenesis (25, 36). However, both excessive (in PAI-1 deficient mice) and deficient 
fibrinolysis (in plasminogen deficient mice) prevent the formation of laser-induced choroidal 
neovascular membranes. The plasminogen/plasminogen activator system is not the only way of 
regulating fibrinolysis. Indeed, a similar role has been demonstrated for members of the MMP 
system. In antiglomerular basement membrane nephritis, MMP-9 is required for fibrinolysis, and 
in its absence, fibrin accumulates in glomeruli (44). We observed that the combined absence of 
both gelatinases resulted in an accumulation of fibrin in laser-induced lesions, which could 
present a physical barrier to the infiltrating cellular components of choroidal neovascularization 
(endothelial cells, fibroblasts, and mononuclear cells). We did not detect mononuclear cells in 
MMP-2,9 deficient mice by immunostaining with MAC-3 antibody, while these inflammatory 
cells were always present at the migrating border of the neovascular membrane in WT controls 
(not shown). 
Is there a place for MMP inhibition in the treatment of choroidal neovascularization? Although 
TIMP-3 has efficacy for the inhibition of the pathological process (45), it also has proapoptotic 
properties, which obviously limit its therapeutic potential in a senescent eye (46). Accordingly, 
we therefore evaluated the effects of TIMP-1 and TIMP-2 with adenoviral delivery. Although 
TIMP-2 overexpression was less efficient than TIMP-1 for the inhibition of in situ gelatinolytic 
activity, it was more effective in preventing the formation of the choroidal reaction. Whether this 
affects the ability of TIMP-2, but not TIMP-1, to inhibit MT1-MMP (42), which is also induced 
in early stages of choroidal neovascularization, formation remains to be determined. MT1-MMP 
could act either through its fibrinolytic activity or through its capacity to activate MMP-2 to 
facilitate choroidal neovascularization. Unfortunately, our experimental model cannot be applied 
to MT1-MMP deficient mice, which die shortly after birth (47). A synthetic MMP inhibitor 
interacting preferentially with MMP-2, MMP-9, and MT1-MMP (Ro 28-2653) inhibited the 
choroidal neovascularization more effectively than the nonspecific inhibitor (Fig. 5F). It is of 
interest to note that similar observations have recently been reported in a tumor model (48). This 
 suggests that broad spectrum inhibition of MMP activity might also repress some beneficial 
MMP effects (49). Indeed, RT-PCR analysis (unpublished data) showed that other MMPs 
(including MMP-8, MMP-12, and MMP-19) are expressed during choroidal neovascularization 
formation the role of which in the disease is at present unknown. MMPs can stimulate 
angiogenesis or generate antiangiogenic factors (such as angiostatin or endostatin) and degrade 
basement membranes, which may limit the extent of angiogenesis at a later stage by destabilizing 
the newly formed blood vessels (10, 11, 50). Altogether, these results suggest that a selective 
inhibition of only some MMPs might be more efficient than an inhibition of the complete MMP 
repertoire for angiogenesis control. 
In conclusion, we have shown that MMP-2 and MMP-9 cooperate in experimental laser-induced 
choroidal neovascularization. In mice with a combined deficiency of both MMP-2 and MMP-9 
genes, both the incidence and the severity of the pathological choroidal reaction were 
significantly reduced, highlighting the differences between physiological (double knockouts 
developed normally) and pathological angiogenesis (51). Since a selective MMP synthetic 
inhibitor could also effectively inhibit subretinal angiogenesis, we believe that inhibition of 
MMP-2, MMP-9, and MT1-MMP may represent a promising strategy for the treatment or for the 
prevention of the exudative form of age-related macular degeneration. 
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Figure 1. Absence of MMP-2 and MMP-9 prevents the development of experimental choroidal neovascularization. 
Hematoxylin-eosin staining of a representative area of choroidal neovascularization at the site of laser-induced trauma in 
control (A) or in mice deficient for MMP-9 (B), MMP-2 (C), and both MMP-2,9 (D). Almost complete absence of 
neovascularization is visible in mice deficient for both MMP-2 and MMP-9 when vessels were immunostained with anti-
mouse PECAM antibody (immunostained in orange with AEC) compared with other conditions, confirming thereby the 
reduced incidence of neovascularization calculated before death by fluorescein angiography evaluation of the number of 
leaking laser spots (F). Neovascular reaction was determined with computer-assisted image analysis by evaluating the 
B/C ratio as described previously (24, 25) at day 14 after laser injury of the Bruch’s membrane in single/double deficient 
mice and in the corresponding WT controls (E). The neural retina (ret) and choroidal layer (ch) are indicated, and the 






Figure 2. Zymographic analysis of MMP-2 and MMP-9 in knockouts and WT mice. At day 5 after the induction of 
choroidal neovascularization by laser, animals were killed and posterior segment extract samples (5 ng/lane) from eyes of 
WT and MMP-2 or MMP-9 deficient mice were analyzed by gelatin zymography (A). As positive control, medium 
conditioned by human HT1080 cells was included ("HT"). Data are the results of a single experiment, which was 1 of 3 
with similar results. In WT mice, a kinetic zymographic evaluation was also performed at different intervals after laser-
induced CNV demonstrating a temporal increase in pro-MMP-9 and the appearance of active forms of MMP-2 (B). In situ 
zymography with fluorescein-conjugated gelatin demonstrates the concentration of gelatinolytic activity at the level of the 
neovascular membrane growing under the retina (C), with limited residual activity at the top of the membrane in double 
MMP-2,9 deficient mice (D). The neural retina (ret) and choroidal layer (Ch) are indicated, and arrows indicate the 






Figure 3. Kinetic evaluation of MMP expression by semiquantitative RT-PCR during the development of 
experimental CNV. The histograms correspond to the densitometric quantification of MMP-2 (A), MMP-9 (B), and 
MT1-MMP (C) mRNA normalized to the 28S signal at different endpoints. Evaluation was performed on the entire 
posterior segment after the induction of multiple wounds to Bruch's membrane. Unlike MMP-2 and TIMP-2 (histogram 
not shown), which remained relatively constant, MMP-9 and MT1-MMP mRNA expression appeared to be induced 







Figure 4. Immunohistochemical staining for fibrinogen/fibrin at the site of laser-induced wound in WT and 
deficient mice. Frozen ocular sections from wild-type (A), MMP-9−/− (B), and MMP-2−/− (C) mice reveal the presence of 
limited amount of fibrin (stained in orange with AEC) in WT mice or single MMP gene-deficient mice contrasting with 
the accumulation of fibrin at the site of restricted choroidal reaction observed in double gene MMP-2,9 deficient animals 




                         
Figure 5. Decreased CNV formation with endogenous or synthetic MMP inhibitors. Systemic injection of adenoviral 
vectors carrying recombinant human TIMP-1 or TIMP-2 resulted in local overexpression of these MMP inhibitors 
demonstrated by semiquantative RT-PCR analysis of injected mice compared with animals injected with control AdRR5 
virus (A-B). Analysis was performed on posterior ocular segments at day 5 after laser-induced choroidal 
neovascularization. In situ zymographic evaluation demonstrates a complete inhibition of gelatinolytic activity with 
AdTIMP-1 transduction, contrasting with signs of residual gelatinolysis with AdTIMP-2 (C-D). Evaluation of the 
choroidal neovascular reaction by B/C ratio calculation showed that both TIMP-1 and TIMP-2 overexpression 
significantly reduced the pathological reaction. TIMP-2 adenoviral-mediated delivery seemed to be more efficient 
(P<0.05) than TIMP-1 local overexpression (E). Evaluation of pharmacological inhibition of MMPs on choroidal 
pathological angiogenesis demonstrated that a selective gelatinase and MT1-MMP synthetic inhibitor administered with 
daily intraperitoneal injections at day 0 or at day 5 after laser induction was much more efficient (P<0.001) that a broad 
spectrum inhibitor (BB-94) (F). The neural retina (ret), and choroidal layer (Ch) are indicated, and the neovascular area is 
arrowed. ***P<0.001; **P<0.01; *P<0.05; error bars = SE. Original magnification = x200. 
